Repurposing FGFR Inhibitor AZD4547 for Neuroblastoma
CSEF · 2018 Biochemistry/ Molecular Biology
Overview
Objectives/Goals The objective of my project was to determine the effect of the FGFR tyrosine kinase inhibitor AZD4547 on cell proliferation, induced apoptosis, and activated pathways in neuroblastoma. I predicted that the drug would inhibit some of the pathways that are active and produce a lower amount of the active phosphorylated form of the proteins than the no drug control. Methods/Materials Neuroblastoma cell lines SK-N-AS, SK-N-SH, SK-N-BE(2), and IMR32 were examined for drug sensitivity to AZD4547 (provided by AstraZeneca) by a confluence assay and an apoptosis assay conducted with the lab's IncuCyte. Three of the four cell lines were found to be more sensitive than the other, probably due to higher expression of FGFR1 and FGFR4 in the latter. To determine which pathways downstream of FGFR were inhibited by the drug, Western Blots were performed to detect the relative protein quantity of total proteins and active proteins. The intensity of phosphorylated protein versus total protein was compared to determine which pathway was affected by the drug. Results I found that AZD4547 treatment resulted in decreased cell confluence and increased rates of apoptosis. AZD4547 treatment also led to decreased phosphorylation of ERK, Akt, and S6K in sensitive cell lines, while the resistant cell line demonstrated reduced inhibition of phosphorylation. Furthermore, sensitive cell line demonstrated increased levels of p-STAT3 while resistant cell line demonstrated decreased or unchanged levels of p-STAT3, suggesting potential markers for AZD4547 response and mechanisms of resistance. Conclusions/Discussion My results demonstrate that AZD4547 has the potential to treat advanced stages of neuroblastoma. The fact that AZD4547 works effectively in only some types of neuroblastoma cell lines indicates that primary screening should occur before patients are treated. I conducted these experiments alongside our lab's assistant, in part because I am too young to work by myself in the lab. I conducted the experiments in this portion of the experiment, while others in the lab conducted other scratch-wound and migration assays with the IncuCyte, while others are now conducting mice experiments to determine the drug's effect in mammals.
Summary statement
I found that the drug AZD4547 was effective in inhibiting the activation of the FGF receptor pathway in neuroblastoma cells, limiting the cells' proliferation and inducing apoptosis.
Help received
I discussed my ideas with the principle investigator I was working under, Dr. Peter Zage of UCSD, and he explained the mechanisms behind protein phosphorylation and the activation of downstream proteins. Anything else I didn't understand I asked Nikki, our lab assistant, and looked up online.
Competition history
- CSEF 2018
Resources
Related projects
CSEF · 2014
Inhibition of Jak2 and PKC Induces Synergistic Apoptosis in Glioblastoma
CSEF · 2016
Identification of MDM2 as a Novel Antiapoptotic Factor in Grade IV Astrocytoma
ISEF · 2018
A Novel Pediatric Cancer Therapy Targeting Epigenetics and Neuroblastoma Differentiation
CSEF · 2017
Efficacy of BIBR1532 in Combination with Nutrient Deprivation on Reduction of Cell Viability in MCF7 and HT1080
ISEF · 2023
Identifying the Molecular Mechanisms of a Safer Neuroblastoma Cure Using the Native Hawaiian 'Awapuhi (Zingiber zerumbet) Herb
ISEF · 2016
The Disruption of SFKs in Neuroblastoma Cells Leads to Decreased Cell Migration
CSEF · 2013
Drug Screening to Identify Novel Therapeutics against Glioblastoma Stem Cells: Year 2
CSEF · 2007
The Effect of Alpha3 Integrin on Neuroblastoma Cell Survival
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: California Science & Engineering Fair public projects